Health

Life-extending prostate cancer drug to be offered to thousands in England

January 16, 2026

The NHS is set to offer the life-extending prostate cancer drug abiraterone to thousands of men in England, expanding its availability to high-risk patients whose cancer has not metastasised. This decision, which follows a campaign by patients and charities, is expected to save approximately 8,000 lives annually.

Close up of white, oval shape Abiraterone tablets, on a shiny, reflective table

Credit: Co

Key Highlights

Abiraterone will be available on the NHS in England for high-risk prostate cancer patients.
The drug has been provided in Scotland and Wales since 2023.
Around 55,300 men are diagnosed with prostate cancer in the UK each year.
The expansion is expected to save approximately 8,000 lives annually.
Previously, abiraterone was only available for the most severe cases.

Health NHS UK news England Society Scotland Cancer Prostate Cancer Men's health

Sources

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Life-extending prostate cancer drug to be offered to thousands in England

Key Highlights

Sources

Related Stories

Cancer survival rates reach record high, but deadliest types still put Americans at risk

The Pitt continues to shine a light on the horrors of the US healthcare system

Measles is spreading fast in S.C. Here's what it says about vaccine exemptions